AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6821809 — intervention group
Group type: COMPARATOR
Intervention: Bacillus Calmette-Guerin (BCG) (Tice)
Number of subjects: 116
Study 29440218 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (active treatment group)
Number of subjects: 336
Study 29440218 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 336
Study 27558421 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Preexposure Prophylaxis (PrEP) with tenofovir
Number of subjects: 100
Study 27558421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 24389648 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia iliaca block
Number of subjects: 2
Study 24389648 — intervention group
Group type: COMPARATOR
Intervention: Standard analgesia
Number of subjects: 2
Study 22727052 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 IU of oxytocin
Number of subjects: 125
Study 22727052 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 IU of oxytocin
Number of subjects: 125
Study 22727052 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 IU of oxytocin
Number of subjects: 125
Study 22727052 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (control group)
Number of subjects: 125
Study 20051921 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryan cervical arthroplasty
Number of subjects: 48
Study 20051921 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion
Number of subjects: 48
Study 19102129 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated remote voice analysis system
Number of subjects: 78
Study 19102129 — intervention group
Group type: COMPARATOR
Intervention: Control patients assessed by standard history, clinical examination, and flexible laryngoscopy or videostroboscopy
Number of subjects: 78
Study 15939628 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual prehension testing using a novel experimental device measuring hand grip forces (GF) and load forces (LF)
Number of subjects: 11
Study 15939628 — intervention group
Group type: COMPARATOR
Intervention: Bimanual prehension testing in neurological patients
Number of subjects: 11
Study 11772951 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.8-4.0 g plant stanol esters daily for 8 weeks
Number of subjects: 44
Study 10680989 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP‐IPV (12.5 Lf, 7 Lf, 40 microg, 40, 8, 32 DU) at 3, 5 and 12 months of age, n = 186
Number of subjects: 270
Study 10680989 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP‐IPV
Number of subjects: 270
Study 10680989 — intervention group
Group type: COMPARATOR
Intervention: DT‐IPV (50 Lf, 12.5 Lf, 40, 8, 32 DU) at 5, 6 and 15 months of age plus whole‐cell pertussis vaccine (> or = 4 IU) at 5 and 9 weeks and at 10 months of age, n = 84
Number of subjects: 270
Study 7892819 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 915
Study 2257857 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 50 mg
Number of subjects: 6
Study 2257857 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine 100 mg
Number of subjects: 6
Study 2257857 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide 5 mg
Number of subjects: 6
Study 2257857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7428646 — intervention group
Group type: EXPERIMENTAL
Intervention: Fendiline (3 X 50 mg)
Number of subjects: 30
Study 7428646 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) (2 X 20 mg plus 1 placebo tablet)
Number of subjects: 30
Study 30401613 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger exercise program with paraffin baths
Number of subjects: 29
Study 30401613 — intervention group
Group type: COMPARATOR
Intervention: Paraffin baths only (Control)
Number of subjects: 29
Study 28254636 — intervention group
Group type: EXPERIMENTAL
Intervention: MIRT (multidisciplinary intensive rehabilitation treatment)
Number of subjects: 34
Study 28254636 — intervention group
Group type: EXPERIMENTAL
Intervention: MIRT-AT (MIRT plus aquatic therapy)
Number of subjects: 34
Study 26340977 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 100
Study 26340977 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet drugs or no antithrombotic treatment (control group)
Number of subjects: 100
Study 23857309 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 58
Study 23857309 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 58
Study 23857309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 23857309 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (minor depression subgroup)
Number of subjects: 58
Study 23857309 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (minor depression subgroup)
Number of subjects: 58
Study 21875862 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 426
Study 19968402 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 93
Study 19968402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 17892026 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management program (3 weeks duration, including small group discussions, workbook completion, and follow-up interviews)
Number of subjects: 27
Study 17892026 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 27
Study 15482763 — intervention group
Group type: EXPERIMENTAL
Intervention: Full excisional surgery
Number of subjects: 39
Study 15482763 — intervention group
Group type: COMPARATOR
Intervention: Placebo surgery
Number of subjects: 39
Study 15482763 — intervention group
Group type: COMPARATOR
Intervention: Initial diagnostic procedure
Number of subjects: 39
Study 15482763 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 39
Study 11806295 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (80 mg/kg, group 1)
Number of subjects: 76
Study 11806295 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 2)
Number of subjects: 76
Study 11117655 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen liquigel 200 mg
Number of subjects: 210
Study 11117655 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen liquigel 400 mg
Number of subjects: 210
Study 11117655 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 210
Study 11117655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 8955970 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 40 micrograms.kg‐1
Number of subjects: 30
Study 8955970 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 1 mg.kg‐1
Number of subjects: 30
Study 8955970 — intervention group
Group type: COMPARATOR
Intervention: Control (no anticholinesterase drug)
Number of subjects: 30
Study 1561531 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g four times a day)
Number of subjects: 71
Study 1561531 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of sucralfate (3 times a day) and ranitidine (300 mg after dinnertime)
Number of subjects: 71
Study 2990189 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat Bran (OB)
Number of subjects: 5
Study 2990189 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus Flour (CF)
Number of subjects: 5
Study 2990189 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat Bran (WB)
Number of subjects: 5
Study 2990189 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn Bran (CB)
Number of subjects: 5
Study 2990189 — intervention group
Group type: COMPARATOR
Intervention: Basal (no added fiber)
Number of subjects: 5
Study 30092443 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloons (DCB)
Number of subjects: 60
Study 30092443 — intervention group
Group type: COMPARATOR
Intervention: Standard Balloon Angioplasty (BA)
Number of subjects: 60
Study 29704513 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg/day
Number of subjects: 573
Study 29704513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 573
Study 27822881 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-based treatment (sofosbuvir and ribavirin with or without pegylated interferon-α)
Number of subjects: 107
Study 25378675 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure management (target systolic BP <140 mm Hg)
Number of subjects: 2909
Study 25378675 — intervention group
Group type: COMPARATOR
Intervention: Guideline-based blood pressure management (target systolic BP <180 mm Hg)
Number of subjects: 2909
Study 23139624 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of bisoprolol fumarate 5 mg
Number of subjects: 18
Study 20850843 — intervention group
Group type: EXPERIMENTAL
Intervention: Incontinence Severity Index
Number of subjects: 0
Study 20850843 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Distress Inventory‐Short Form 20
Number of subjects: 0
Study 20850843 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary Distress Inventory‐Short Form
Number of subjects: 0
Study 20850843 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Impact Questionnaire‐Short Form 7
Number of subjects: 0
Study 20850843 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder diary
Number of subjects: 0
Study 17921387 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient mix (iron, zinc, folate, vitamins A, B-6, B-12, and C)
Number of subjects: 780
Study 17921387 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (88 mg/d) and EPA (22 mg/d)
Number of subjects: 780
Study 17921387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 780
Study 17921387 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA+EPA
Number of subjects: 780
Study 16251241 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalfurafine
Number of subjects: 144
Study 16251241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 12382292 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spa therapy and exercise therapy (Group 1)
Number of subjects: 120
Study 12382292 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spa therapy and exercise therapy (Group 2)
Number of subjects: 120
Study 12382292 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual activities and standard treatment)
Number of subjects: 120
Study 10450748 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF) 5 microg/kg/day subcutaneously during and after chemotherapy
Number of subjects: 64
Study 10450748 — intervention group
Group type: COMPARATOR
Intervention: Control group (no G-CSF)
Number of subjects: 64
Study 10450748 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF)
Number of subjects: 64
Study 7802368 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanic membrane thermometry (TM)
Number of subjects: 32
Study 2319003 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally positioned surgical flap
Number of subjects: 19
Study 2319003 — intervention group
Group type: COMPARATOR
Intervention: Dura mater membrane
Number of subjects: 19
Study 31082790 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet plus 40 g/d of oat bran
Number of subjects: 154
Study 31082790 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie diet only
Number of subjects: 154
Study 31082790 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 154
Study 28689306 — intervention group
Group type: EXPERIMENTAL
Intervention: Spine-strengthening exercise and posture training (1 hour, three times weekly for 6 months)
Number of subjects: 99
Study 28689306 — intervention group
Group type: EXPERIMENTAL
Intervention: Spine-strengthening exercise and posture training
Number of subjects: 99
Study 28689306 — intervention group
Group type: COMPARATOR
Intervention: Control group (four group health education meetings)
Number of subjects: 99
Study 23511339 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 0.25 mg/kg per day
Number of subjects: 75
Study 23511339 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 1 mg/kg per day
Number of subjects: 75
Study 23511339 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 4 mg/kg per day
Number of subjects: 75
Study 23511339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 20834026 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel risk biomarkers (plasma tHcy, red cell folate)
Number of subjects: 133
Study 20834026 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 133
Study 20834026 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel risk biomarkers (plasma tHcy, RCF levels)
Number of subjects: 133
Study 19440084 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (n = 16)
Number of subjects: 28
Study 19440084 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 28
Study 17311892 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant intravenous ghrelin infusion at 5 pmol.kg body wt(‐1).min(‐1) for 180 min
Number of subjects: 0
Study 15502049 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg tramadol
Number of subjects: 40
Study 15502049 — intervention group
Group type: COMPARATOR
Intervention: 1 mg/kg lidocaine
Number of subjects: 40
Study 11208825 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH agonist plus tamoxifen
Number of subjects: 506
Study 11208825 — intervention group
Group type: COMPARATOR
Intervention: LHRH agonist alone
Number of subjects: 506
Study 9389419 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide 30 microg four times per day
Number of subjects: 215
Study 9389419 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide 30 microg three times per day (BLD)
Number of subjects: 215
Study 9389419 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide 30 microg three times per day (BDS)
Number of subjects: 215
Study 9389419 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide 60 microg twice per day
Number of subjects: 215
Study 9389419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 7534161 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms/kg/day of rhG‐CSF starting 1 day after BM reinfusion (day +1 group, n = 25 patients)
Number of subjects: 78
Study 7534161 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms/kg/day of rhG‐CSF starting 6 days after BM reinfusion (day +6 group, n = 24 patients)
Number of subjects: 78
Study 7534161 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (n = 29 patients)
Number of subjects: 78
Study 3349825 — intervention group
Group type: EXPERIMENTAL
Intervention: Gravity-resistance (GR) upper-extremity training
Number of subjects: 45
Study 3349825 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified proprioceptive neuromuscular facilitation (PNF) upper-extremity training
Number of subjects: 45
Study 3349825 — intervention group
Group type: COMPARATOR
Intervention: No upper-extremity training (control)
Number of subjects: 45
Study 3349825 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 45
Study 31237716 — intervention group
Group type: EXPERIMENTAL
Intervention: UD + CAD (Ultrasound Doctor with Computer-Aided Diagnosis)
Number of subjects: 454
Study 31237716 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD (Computer-Aided Diagnosis)
Number of subjects: 454
Study 31237716 — intervention group
Group type: EXPERIMENTAL
Intervention: AmCAD software
Number of subjects: 454
Study 31237716 — intervention group
Group type: COMPARATOR
Intervention: UD (Ultrasound Doctor)
Number of subjects: 454
Study 29028980 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 1761
Study 29028980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1761
Study 26272769 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolapitant (180 mg dose)
Number of subjects: 1087
Study 26272769 — intervention group
Group type: COMPARATOR
Intervention: Active control (placebo)
Number of subjects: 1087
Study 23967630 — intervention group
Group type: EXPERIMENTAL
Intervention: Scraping technique of stuck needle at Anmian (Extra)
Number of subjects: 131
Study 23967630 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture (Sanyinjiao, Shenmen, Baihui)
Number of subjects: 131
Study 21524156 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (PIP/TAZO)
Number of subjects: 42
Study 21524156 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin/tazobactam plus amikacin
Number of subjects: 42
Study 18478022 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram infusion (10 mg)
Number of subjects: 4
Study 18478022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 16926562 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pyloromyotomy
Number of subjects: 200
Study 16926562 — intervention group
Group type: COMPARATOR
Intervention: Open pyloromyotomy
Number of subjects: 200
Study 16926562 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study 15339608 — intervention group
Group type: EXPERIMENTAL
Intervention: Qiangxin Mixture
Number of subjects: 60
Study 15339608 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 60
Study 10985439 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill re-training
Number of subjects: 18
Study 10985439 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 18
Study 9389015 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (5 mg)
Number of subjects: 40
Study 9389015 — intervention group
Group type: COMPARATOR
Intervention: Vit-C (0.1 g)
Number of subjects: 40
Study 1533588 — intervention group
Group type: EXPERIMENTAL
Intervention: fosinopril 20 mg daily
Number of subjects: 24
Study 1533588 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 3907991 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release tablet of ketoprofen (200 mg once daily)
Number of subjects: 84
Study 3907991 — intervention group
Group type: COMPARATOR
Intervention: Normal ketoprofen capsules (2 X 50 mg twice daily)
Number of subjects: 84
Study 3907991 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release tablet of ketoprofen
Number of subjects: 84
Study 3907991 — intervention group
Group type: COMPARATOR
Intervention: Normal ketoprofen capsules
Number of subjects: 84
Study 3907991 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 84
Study 29558909 — intervention group
Group type: EXPERIMENTAL
Intervention: IOL A (Ophtec Precizon)
Number of subjects: 202
Study 29558909 — intervention group
Group type: EXPERIMENTAL
Intervention: IOL B (Lucid Korea Microflex)
Number of subjects: 202
Study 29558909 — intervention group
Group type: EXPERIMENTAL
Intervention: IOL C (Carl Zeiss Asphina)
Number of subjects: 202
Study 28249845 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 90
Study 28249845 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 90
Study 25732215 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (9 grams)
Number of subjects: 22
Study 25732215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 23945887 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobutton
Number of subjects: 120
Study 23945887 — intervention group
Group type: EXPERIMENTAL
Intervention: Aperfix
Number of subjects: 120
Study 23945887 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigidfix
Number of subjects: 120
Study 20450413 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor therapy
Number of subjects: 395
Study 18441389 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin stimulation for 3 hours
Number of subjects: 2
Study 16749289 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive strategy based on early coronary angiography and subsequent revascularization; specific dosage and duration not available.
Number of subjects: 0
Study 16749289 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (beta-blockers, aspirin, statins); specific dosage and duration not available.
Number of subjects: 0
Study 15161452 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi
Number of subjects: 118
Study 15161452 — intervention group
Group type: COMPARATOR
Intervention: Low-impact exercise (Control)
Number of subjects: 118
Study 10958124 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo analgesic injection (saline IM injection resembling ketorolac 60 mg)
Number of subjects: 64
Study 10958124 — intervention group
Group type: COMPARATOR
Intervention: Placebo oral analgesia (inactive starch tablet resembling ibuprofen 800 mg)
Number of subjects: 64
Study 9065610 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg po daily
Number of subjects: 156
Study 8349838 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% w/w flurbiprofen toothpaste, used 2 x daily for 12 months
Number of subjects: 49
Study 8349838 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 49
Study 8349838 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% w/w flurbiprofen toothpaste
Number of subjects: 49
Study 3555035 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg of oral ciprofloxacin every 12 hours for two weeks
Number of subjects: 29
Study 3555035 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg of oral ciprofloxacin every 12 hours for two weeks
Number of subjects: 29
Study 3555035 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin therapy
Number of subjects: 29
Study 31899529 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual education via handheld tablet with self-assessment questions, narrated video demonstration, and iterative rounds as needed.
Number of subjects: 118
Study 31899529 — intervention group
Group type: COMPARATOR
Intervention: In-person education with iterative rounds of inhaler technique assessment and education by trained staff.
Number of subjects: 118
Study 29252048 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-brokered self-directed care intervention
Number of subjects: 46